

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

**1. -8. (canceled).**

**9. (currently amended):** A method for measuring an occupying ratio of a compound bound to a strong binding site of CCR5 on a CCR5 expressing cell or a membrane fraction thereof, which comprises

- (a) allowing a CCR5 expressing cell or a membrane fraction thereof to contact with a compound to be tested,
- (b) allowing the test compound-bound cell or a membrane fraction thereof prepared in the above step (a) to contact with a labeled anti-CCR5 antibody, wherein when an antagonist or an agonist is bound to the strong binding site of CCR5, the antibody has a property of not binding to CCR5, or an isotype control of the labeled anti-CCR5 antibody, and
- (c) calculating an occupying ratio of the compound bound to the strong binding site of CCR5 on the cell or membrane fraction thereof, based on the ratio of:  
\_\_\_\_\_a bound amount of the anti-CCR5 antibody when the compound is bound to CCR5  
corrected by using the isotype control to  
\_\_\_\_\_a bound amount of the anti-CCR5 antibody when the compound is not bound to CCR5  
corrected by using the isotype control, which is defined as 100%.

**10.-32 (canceled).**

**33. (new):** The method according to claim 9, wherein the anti-CCR5 antibody is 45531.111 antibody and/or 45523.111 antibody.